Rationality evaluation of alteplase in the treatment of acute ischemic stroke based on weighted TOPSIS method

Published on Jul. 02, 2024Total Views: 970 times Total Downloads: 272 times Download Mobile

Author: GUO Sitong ¹ CAI Huiya ² SU Henghai ¹  ZHANG Jinhua ³

Affiliation: 1. Department of Pharmacy, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning 530000, China 2. Department of Pharmacy, The Second Hospital of Zhangzhou, Zhangzhou 363199, Fujian Province, China 3. Department of Pharmacy, Fujian Maternity and Child Health Care Hospital, Fuzhou 350001, China

Keywords: Alteplase Acute ischemic stroke Drug use evaluation Weighted TOPSIS method Rational drug use

DOI: 10.12173/j.issn.1005-0698.202312044

Reference: GUO Sitong, CAI Huiya, SU Henghai, ZHANG Jinhua.Rationality evaluation of alteplase in the treatment of acute ischemic stroke based on weighted TOPSIS method[J].Yaowu Liuxingbingxue Zazhi,2024, 33(6):642-651.DOI: 10.12173/j.issn.1005-0698.202312044.[Article in Chinese]  Copied

Abstract
Full-text
References

Abstract

Objective To establish a drug use evaluation (DUE) criteria for alteplase in the treatment of acute ischemic stroke (AIS), and to evaluate the use of the drug by weighted TOPSIS method, to provide a reference for rational use of alteplase.

Methods Based on the drug package insert, relevant guidelines, the DUE criteria for alteplase in the treatment of AIS were developed combined with expert consultation. The weighted TOPSIS method was used to evaluate the rationality of alteplase use in inpatients with AIS in the People's Hospital of Guangxi Zhuang Autonomous Region from January 2020 to June 2022, based on the attribute hierarchy model.

Results A total of 126 medical records were included. Among them, 80 cases (63.49%) exhibited a high degree of adherence (C_i > 0.8) between the prescribed drug regimens and the optimal recommendations, which was considered reasonable. Additionally, 40 cases (31.75%) fell within the range of 0.6 ≤ C_i ≤ 0.8, indicating a basic reasonable adherence, and 6 cases (4.76%) had a C_i < 0.6, suggesting an unreasonable level of adherence. The irrational use of the drug mainly involved contraindications (32.54%), dosage (7.14%), and drug conversion (7.14%), among other aspects.

Conclusion The weighted TOPSIS method is used to evaluate the rationality of alteplase in the treatment of acute ischemic stroke (AIS), and the results are intuitive and comprehensive. There are still problems in the use of alteplase in this hospital, and it is necessary to strengthen intervention to promote rational clinical use of alteplase in terms of contraindication of medication and dosage, etc.

Full-text

Please download the PDF version to read the full text: download

References

1.苟亚军, 胡俊, 李迎春, 等. 远程医疗会诊在区域化网络协同诊治急性缺血性脑卒中的应用研究[J]. 第三军医大学学报, 2020, 42(19): 1965-1970. [Gou YJ, Hu J, Li YC, et al. Application of telemedicine consultation system in coordination of regionalization network for diagnosis and treatment of acute ischemic stroke[J]. Journal of Army Medical University, 2020, 42(19): 1965-1970.] DOI: 10.16016/j.1000-5404.202006245.

2.郝春华, 李亚丽, 孙双勇, 等. 缺血性脑中风急性期溶栓药物研究进展[J]. 中国新药杂志, 2015, 24(23): 2687-2691. [Hao CH, Li YL, Sun SY, et al. Advances of thrombolytics in acute phase of ischemic stroke[J]. Chinese Journal of New Drugs, 2015, 24(23): 2687-2691.] DOI: CNKI:SUN:ZXYZ.0.2015-23-013.

3.Tan EC, George J, Stewart K, et al. Improving osteoporosis management in general practice: a pharmacist-led drug use evaluation program[J]. Drugs Aging, 2014, 31(9): 703-709. DOI: 10.1007/s40266-014-0194-0.

4.Rosić M, Pešić D, Kukić D, et al. Method for selection of optimal road safety composite index with examples from DEA and TOPSIS method[J]. Accid Anal Prev, 2017, 98: 277-286. DOI: 10.1016/j.aap.2016.10.007.

5.Berge E, Whiteley W, Audebert H, et al. European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke[J]. Eur Stroke J, 2021, 6(1): Ⅰ-LⅫ. DOI: 10.1177/2396987321989865.

6.中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2018[J]. 中华神经科杂志, 2018, 51(9): 666-682. DOI: 10.3760/cma.j.issn.1006-7876.2018.09.004.

7.国家卫生健康委脑卒中防治工程委员会, 编. 中国脑卒中防治指导规范[M]. 北京: 人民卫生出版社, 2021: 1-300.

8.《中国血栓性疾病防治指南》专家委员会. 中国血栓性疾病防治指南[J]. 中华医学杂志, 2018, 98(36): 2861-2888. DOI: 10.3760/cma.j.issn.0376-2491.2018.36.002.

9.蒋莹莹, 詹尧平, 徐翔翔. LIKERT 五分量表法在建立儿科人血白蛋白临床应用评价标准的应用[J]. 儿科药学杂志, 2023, 29(1): 1-4. [Jiang YY, Zhan YP, Xu XX. Establishment and application of clinical evaluation criteria for pediatric human serum albumin based on Likert five subscale method[J]. Journal of Pediatric Pharmacy, 2023, 29(1): 1-4.] DOI: 10.13407/j.cnki.jpp.1672-108X. 2023.01.001.

10.Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions[J]. Clin Pharmacol Ther, 1981, 30(2): 239-245. DOI: 10.1038/clpt.1981.154.

11.李瑞娟, 李美娟, 米小龙, 等. 基于加权TOPSIS法的注射用比伐芦定药物利用评价[J]. 药物流行病学杂志, 2024, 33(4): 361-370. [Li RJ, Li MJ, Mi XL, et al. Drug use evaluation of bivalirudin for injection based on weighted TOPSIS method[J]. Chinese Journal of Pharmacoepidemiology, 2024, 33(4): 361-370.] DOI: 10.12173/j.issn.1005-0698.202306020.

12.袁浩宇, 易红, 胡明, 等. 头孢吡肟DUE标准的建立 [J].中国药房, 2010, 21(26): 2479-2482. [Yuan HY, Yi H, Hu M, et al. Establishment of DUE standard for cefepime [J]. Chinese Pharmacy, 2010, 21(26): 2479-2482.] DOI: CNKI:SUN:ZGYA.0.2010-26-038.

13.Sevastjanov P, Tikhonenko A. Direct interval extension of TOPSIS method[C]. International Conference on Parallel Processing and Applied Mathematics, Poland: Lecture Notes in Computer Science, 2012, 7204: 504-512.

14.毕玉侠. 我国药品不良反应评价研究[D]. 沈阳: 沈阳药科大学, 2010.

15.Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. definitions for use in a multicenter clinical trial. TOAST. trial of org 10172 in acute stroke treatment[J]. Stroke, 1993, 24(1): 35-41. DOI: 10.1161/01.str.24.1.35.

16.朱珊珊, 王娜, 蔡慧雅, 等. 基于加权TOPSIS法的奥扎格雷钠药物利用评价[J]. 药物流行病学杂志, 2024, 33(2): 137-144. [Zhu SS, Wang N, Cai HY, et al. Drug use evaluation of ozagrel sodium based on weighted TOPSIS method[J]. Chinese Journal of Pharmacoepidemiologyl, 2024, 33(2): 137-144.] DOI: 10.12173/j.issn.1005-0698.202306022.

17.Qureshi AI, Ezzeddine MA, Nasar A, et al. Prevalence of elevated blood pressure in 563,704 adult patients with stroke presenting to the ED in the United States[J]. Am J Emerg Med, 2007, 25: 32-38. DOI: 10.1016/j.ajem.2006.07.008.

18.吴敌, 王伊龙, 周永, 等. 北京市11家医院缺血性卒中和短暂性脑缺血发作患者血压控制状况的横断面调査[J]. 中国卒中杂志, 2009, 4(6): 464-469. [Wu D, Wang YL, Zhou Y, et al. Cross sectional survey of blood pressure control in patients with ischemic stroke and transient ischemic attack in 11 hospitals in Beijing [J]. Chinese Journal of Stroke, 2009, 4(6): 464-469.] DOI: 10.3969/j.issn.1673-5765.2009.06.006.

19.Yong M, Kaste M. Association of characteristics of blood pressure profiles and stroke outcomes in the ECASS-II trial[J]. Stroke, 2008, 39: 366-372. DOI: 10.1161/STROKEAHA.107.492330.

20.Tsivgoulis G, Frey JL, Flaster M, et al. Pre-tissue plasminogen activator blood pressure levels and risk of symptomatic intracerebral hemorrhage[J]. Stroke, 2009, 40: 3631-3634. DOI: 10.1161/STROKEAHA.109.564096.

21.Berge E, Cohen G, Lindley RI, et al. Effects of blood pressure and blood pressure-lowering treatment during the first 24 hours among patients in the third international stroke trial of thrombolytic treatment for acute ischemic stroke[J]. Stroke, 2015, 46: 3362-3369. DOI: 10.1161/STROKEAHA.115.010319.

22.Mundiyanapurath S, Hees K, Ahmed N, et al. Predictors of symptomatic intracranial haemorrhage in off-label thrombolysis: an analysis of the safe implementation of treatments in stroke registry[J]. Eur J Neurol, 2018, 25: e340-e311. DOI: 10.1111/ene.13507.

23.Wang X, Robinson TG, Lee TH, et al. Low-dose vs standard-dose alteplase for patients with acute ischemic stroke: secondary analysis of the ENCHANTED randomized clinical trial[J]. JAMA Neurol, 2017, 74(11): 1328-1335. DOI: 10.1001/jamaneurol.2017.2286.

24.Anderson CS, Robinson T, Lindley RI, et al. Low-dose versus standard-dose intravenous alteplase in acute ischemic stroke[J]. N Engl J Med, 2016, 374(24): 2313-2323. DOI: 10.1056/NEJMoa1515510.

25.Liao X, Wang Y, Pan Y, et al. Standard-dose intravenous tissue-type plasminogen activator for stroke is better than low doses[J]. Stroke, 2014, 45(8): 2354-2358. DOI: 10.1161/STROKEAHA.114.005989.

26.Kim BJ, Han MK, Park TH, et al. Low-versus standard-dose alteplase for ischemic strokes within 4.5 hours: a comparative effectiveness and safety study[J]. Stroke, 2015, 46(9): 2541-2518. DOI: 10.1161/STROKEAHA.115.010180.

27.Nakagawara J, Minematsu K, Okada Y, et al. Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice: the Japan post-marketing alteplase registration study (J-MARS) [J]. Stroke, 2010, 41(9): 1984-1989. DOI: 10.1161/STROKEAHA.110.589606.

28.Mori E, Minematsu K, Nakagawara J, et al. Effects of 0.6 mg/kg intravenous alteplase on vascular and clinical outcomes in middle cerebral artery occlusion: Japan alteplase clinical trial Ⅱ (J-ACT Ⅱ)[J]. Stroke, 2010, 41(3): 461-465. DOI: 10.1161/STROKEAHA.109.573477.

29.Alexandrov AV, Grotta JC. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator[J]. Neurology, 2002, 59: 862-867. DOI: 10.1212/wnl.59.6.862.

30.Rubiera M, Alvarez-Sabin J, Ribo M, et al. Predictors of early arterial reocclusion after tissue plasminogen activator-induced recanalization in acute ischemic stroke[J]. Stroke, 2005, 36: 1452-1456. DOI: 10.1161/01.STR.0000170711.43405.81.

31.Barreto AD, Alexandrov AV. Adjunctive and alternative approaches to current reperfusion therapy[J]. Stroke, 2012, 43: 591-598. DOI: 10.1161/STROKEAHA.111.617902.

32.Harsany M, Tsivgoulis G, Alexandrov AV. Intravenous thrombolysis in acute ischemic stroke: standard and potential future applications[J]. Expert Rev Neurother, 2014, 14: 879-892. DOI: 10.1586/14737175.2014. 934676.